比较NICE指南与联合母体因素和生物标志物方法对子痫前期早期筛查诊断准确性的SPREE研究结果
SPREE前瞻性多中心研究纳入16747例孕11-13周单胎妊娠,比较NICE指南方法与贝叶斯联合母体因素和生物标志物方法筛查子痫前期的效能,结果显示贝叶斯方法对早产型子痫前期的检出率显著优于NICE方法,而NICE方法的筛查效能较差且指南依从性低。
要点
- NICE方法筛查阳性率10.3%,对所有子痫前期检出率30.4%,对早产型子痫前期检出率40.8%。
- 联合母体因素、MAP和PlGF筛查早产型子痫前期检出率69.0%,较NICE方法提高28.2%。
- 再加UtA-PI后早产型子痫前期检出率82.4%,较NICE方法提高41.6%。
核心结论
- NICE指南推荐的子痫前期筛查效能较差,且对该指南的依从性低;联合母体因素与生物标志物的方法可大幅提高筛查效能。
研究设计与样本
- 前瞻性多中心研究(SPREE),纳入英格兰七家国民健康服务体系产科医院2016年4月至12月招募的孕11-13周单胎妊娠孕妇,共16747例。
诊断标准与关键数值
- NICE方法筛查阳性率10.3%,对所有子痫前期检出率30.4%,对早产型子痫前期(需在37周前分娩)检出率40.8%。
- 小型联合试验(母体因素、MAP和PAPP-A)对所有子痫前期检出率42.5%,较NICE方法提高12.1%(95%CI 7.9-16.2%)。
- 联合母体因素、MAP和PlGF筛查早产型子痫前期检出率69.0%,较NICE方法提高28.2%(95%CI 19.4-37.0%)。
- 联合母体因素、MAP、UtA-PI和PlGF筛查早产型子痫前期检出率82.4%,较NICE方法提高41.6%(95%CI 33.2-49.9%)。
临床应用与阅片要点
- 对早产型子痫前期,联合母体因素、MAP、PlGF和UtA-PI的贝叶斯方法检出率高于NICE方法。
- NICE指南建议子痫前期高风险孕妇从孕早期至妊娠结束服用阿司匹林,但依从率仅23%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To test the hypothesis that the performance of first-trimester screening for pre-eclampsia (PE) by a method that uses Bayes' theorem to combine maternal factors with biomarkers is superior to that defined by current National Institute for Health and Care Excellence (NICE) guidelines.
METHODS: This was a prospective multicenter study (screening program for pre-eclampsia (SPREE)) in seven National Health Service maternity hospitals in England, of women recruited between April and December 2016. Singleton pregnancies at 11-13 weeks' gestation had recording of maternal characteristics and medical history and measurements of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A). The performance of screening for PE by the Bayes' theorem-based method was compared with that of the NICE method. Primary comparison was detection rate (DR) using NICE method vs mini-combined test (maternal factors, MAP and PAPP-A) in the prediction of PE at any gestational age (all-PE) for the same screen-positive rate determined by the NICE method. Key secondary comparisons were DR of screening recommended by the NICE guidelines vs three Bayes' theorem-based methods (maternal factors, MAP and PAPP-A; maternal factors, MAP and PlGF; and maternal factors, MAP, UtA-PI and PlGF) in the prediction of preterm PE, defined as that requiring delivery < 37 weeks.
RESULTS: All-PE developed in 473 (2.8%) of the 16 747 pregnancies and preterm PE developed in 142 (0.8%). The screen-positive rate by the NICE method was 10.3% and the DR for all-PE was 30.4% and for preterm PE it was 40.8%. Compliance with the NICE recommendation that women at high risk for PE should be treated with aspirin from the first trimester to the end of pregnancy was only 23%. The DR of the mini-combined test for all-PE was 42.5%, which was superior to that of the NICE method by 12.1% (95% CI, 7.9-16.2%). In screening for preterm PE by a combination of maternal factors, MAP and PlGF, the DR was 69.0%, which was superior to that of the NICE method by 28.2% (95% CI, 19.4-37.0%) and with the addition of UtA-PI the DR was 82.4%, which was higher than that of the NICE method by 41.6% (95% CI, 33.2-49.9%).
CONCLUSIONS: The performance of screening for PE as currently recommended by NICE guidelines is poor and compliance with these guidelines is low. The performance of screening is substantially improved by a method combining maternal factors with biomarkers. © 2018 Crown copyright. Ultrasound in Obstetrics & Gynecology © 2018 ISUOG.
引用
- Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018. PMID: 29536574. doi:10.1002/uog.19039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。